Joachim G. Aerts
Experienced in Bronchiectasis

Joachim G. Aerts

Erasmus MC
Rotterdam, ZH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Bronchiectasis
Erasmus MC
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Joachim Aerts practices in Rotterdam, Netherlands. Mr. Aerts is rated as an Experienced expert by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD), and Lung Transplant.

His clinical research consists of co-authoring 288 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Bronchiectasis.

Gender
Male

Locations

Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Durvalumab, Carboplatin, Paclitaxel
Study Phase: Phase 2
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage Non-small Cell Lung Cancer HAMLET Study
Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage Non-small Cell Lung Cancer HAMLET Study
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Procedure, Radiation
Study Phase: Not Applicable
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Enrollment Status: Unknown
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: May 10, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)
A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)
Enrollment Status: Completed
Publish Date: September 29, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12
A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12
Enrollment Status: Completed
Publish Date: September 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy A Prospective Study of Caphosol + Standard of Care Versus Standard of Care
The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy A Prospective Study of Caphosol + Standard of Care Versus Standard of Care
Enrollment Status: Terminated
Publish Date: April 07, 2020
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)
A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)
Enrollment Status: Terminated
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma
A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: September 25, 2018
Intervention Type: Drug, Device
Study Phase: Phase 2
View 11 Less Clinical Trials

288 Total Publications

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Aerts's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile